

EXPAND ACCESS TO BIOMARKER TESTING IN OKLAHOMA


THE RIGHT TREATMENT AT THE RIGHT TIME

WHAT IS BIOMARKER TESTING?

Biomarker testing is often used to help determine the best treatment for a patient.

- It is the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker.
- Biomarker testing is an important step for accessing precision medicine, including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients.
- While most current applications of biomarker testing are in oncology and autoimmune disease, there is research underway to benefit patients with other conditions including heart disease, neurological conditions like Alzheimer's disease, infectious disease and respiratory illness.

THE IMPORTANCE OF BIOMARKER TESTING



BIOMARKER TESTING & HEALTH EQUITY

- **Not all communities in Oklahoma are benefitting from the latest advancements in biomarker testing and precision medicine.**
 - Patients who are older, Black, uninsured or Medicaid-insured, are less likely to be tested for certain guideline-indicated biomarkers.
 - There are lower rates of testing in community settings versus academic medical centers.

THE BOTTOM LINE


Access to appropriate biomarker testing can help to achieve:

- better health outcomes
- improved quality of life
- reduced costs

Insurance coverage for biomarker testing is failing to keep pace with innovation and advancement in treatment:

- Without action, this could increase existing disparities in cancer outcomes by race, ethnicity, income and geography.

Arizona, Illinois, Louisiana and Rhode Island have recently passed legislation to expand coverage of comprehensive biomarker testing.



In Oklahoma:



BENEFITS OF BIOMARKER TESTING FOR OKLAHOMA PATIENTS

Using the biomarker testing, my doctors were able to lay out a treatment plan that specifically targeted my cancers. Today, there is no cancer anywhere in my body... I'm fully alive and really, without the biomarker testing and targeted therapy, I don't think I would be.



Carla Prothro, Texas

SUPPORTERS OF OKLAHOMA BIOMARKER TESTING LEGISLATION [SB513]




For more information please contact:

Matt Glanville, ACS CAN Oklahoma Government Relations Director

✉ Matt.Glanville@cancer.org

☎ 405.301.6311

SUPPORTERS OF OKLAHOMA BIOMARKER TESTING LEGISLATION [SB513]



For more information please contact:
 Matt Glanville, ACS CAN Oklahoma Government Relations Director
 ✉ Matt.Glanville@cancer.org ☎ 405.301.6311